Ixabepilone in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer That Has Not Responded to Previous Chemotherapy

Primary Peritoneal Cavity Cancer Clinical Trial

Official title:

A Phase II Evaluation of Epothilone-B BMS 247550 (NSC # 710428) in the Treatment of Recurrent or Persistent Platinum and Paclitaxel Refractory Ovarian or Primary Peritoneal Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00025155
• Other study ID #: NCI-2012-02413
• Secondary ID: NCI-2012-02413CD
• Status: Completed
• Phase: Phase 2
• Start date: July 2002
• Est. completion date: March 2010

Study information

• Verified date: July 2019
• Source: National Cancer Institute (NCI)
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Phase II trial to study the effectiveness of ixabepilone in treating patients who have recurrent or persistent ovarian epithelial or primary peritoneal cancer that has not responded to previous chemotherapy. Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die.

Description:

PRIMARY OBJECTIVES:

I. Determine the antitumor activity of ixabepilone in patients with recurrent or persistent platinum and paclitaxel-refractory ovarian epithelial or primary peritoneal cancer.

II. Determine the nature and degree of toxicity of this drug in these patients.

OUTLINE:

Patients receive ixabepilone IV over 1 hour. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients with a complete response (CR) receive 2 additional courses after achieving CR.

Patients are followed every 3 months for 2 years and then every 6 months for 3 years.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 51
• Est. completion date: March 2010
• Est. primary completion date: March 2010
• Accepts healthy volunteers: No
• Gender: Female
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Histologically confirmed ovarian epithelial cancer or primary peritoneal cancer

• Recurrent or persistent disease

• Platinum AND taxane-resistant or refractory disease

• Progressed during therapy

• Refractory disease within 6 months of therapy

• Measurable disease

• At least 20 mm by conventional techniques

• At least 10 mm by spiral CT scan

• Tumor lesions located within a previously irradiated field are not considered measurable disease unless there is documented tumor progression in these lesions or biopsy confirmation = 90 days following completion of radiotherapy

• Ineligible for higher priority GOG (Gynecologic Oncology Group) protocol

• No active brain metastases

• Performance status - GOG 0-2

• Absolute neutrophil count = 1,500/mm^3

• Platelet count = 100,000/mm^3

• Bilirubin = 1.5 times upper limit of normal (ULN)

• SGOT (serum glutamate oxaloacetate transaminase) = 2.5 times ULN

• Alkaline phosphatase = 2.5 times ULN

• Creatinine = 1.5 times ULN

• No sensory or motor neuropathy > grade 1

• No dementia or altered mental status

• No other serious uncontrolled medical disorder

• No active infection requiring antibiotics

• No prior hypersensitivity reaction to paclitaxel or other therapy containing Cremophor EL

• No other malignancy within the past 5 years except nonmelanoma skin cancer

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception

• At least 3 weeks since prior biologic therapy

• At least 3 weeks since prior immunotherapy

• Must have received:

• 1 prior combination taxane-based and platinum-based chemotherapy regimen

• 1 prior platinum-based chemotherapy regimen AND 1 prior taxane-based chemotherapy regimen

• Initial treatment may include high-dose therapy, consolidation, or extended therapy

• At least 3 weeks since prior chemotherapy and recovered

• No prior ixabepilone

• No other prior cytotoxic chemotherapy for recurrent or persistent disease, including treatment with initial regimen

• At least 1 week since prior hormonal anticancer therapy

• Concurrent hormone replacement therapy allowed

• At least 3 weeks since prior radiotherapy and recovered

• No prior radiotherapy to site(s) of measurable disease

• No radiotherapy to > 25% of marrow-containing areas

• Recovered from recent surgery

• At least 3 weeks since other anticancer therapy

• No prior anticancer therapy that precludes study participation

• No concurrent food supplements (e.g., St. John's wort)

• No concurrent amifostine or other protective agents

Related Conditions & MeSH terms

• Carcinoma, Ovarian Epithelial
• Primary Peritoneal Cavity Cancer
• Recurrent Ovarian Epithelial Cancer

Intervention

Drug:
• ixabepilone
Given IV

Locations

Country	Name	City	State
United States	Gynecologic Oncology Group	Philadelphia	Pennsylvania

Sponsors (2)

Lead Sponsor	Collaborator
National Cancer Institute (NCI)	Gynecologic Oncology Group

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Tumor Response	Percentage of participants with complete and partial tumor response as assessed by the Gynecologic Oncology Group Response Evaluation Criteria in Solid Tumors (GOG RECIST) with one-sided 90% Confidence Interval.; Complete Response (CR), disappearance of all target and non-target lesions without evidence of new lesion; Partial Response (PR), >=30% decrease in the sum of the longest dimensions (LD) of all target measurable lesions taking as reference the baseline sum of LD with no unequivocal progression of non-target lesions and no evidence of new lesion, or a 50% decrease in the LD in the case where the ONLY target lesion is a solitary pelvic mass measured by physical exam with no unequivocal progression of non-target lesions and no evidence of new lesion. Complete or partial response requires confirmation at greater than or equal to 4 weeks from initial documentation.	Every other cycle until the completion of study treatment with an average of study treatment time as of 3 months.
Primary	Number of People With Adverse Effects		Every cycle until completion of study treatment up to 30 days after stopping study treatment
Secondary	Progression Free Survival	Progression-Free Survival is the period from study entry until disease progression, death or date of last contact, whichever occurs first.; Progression is defined as at least a 20% increase in the sum of the longest dimensions (LD) of target lesions taking as reference the smallest sum LD recorded since study entry, or a 50% increase in the LD taking as reference the smallest LD recorded since study entry in the case where the ONLY target lesion is a solitary pelvic mass measured by physical exam, or unequivocal progression of existing non-target lesions, or the appearance of one or more new lesions, or global deterioration in health status attributable to the disease requiring a change in therapy without objective evidence of progression, or death due to disease without prior objective documentation of progression.	From study entry to disease progression, death or date of last contact, whichever occurs first. Every other cycle, up to 5 years of follow-up
Secondary	Overall Survival	Overall survival is defined as the duration of time from study entry to time of death or the date of last contact.	From study entry to death or last contact, up to 5 years of follow-up.